Evotec AG O.N. (EVTG)

18.810
-0.105(-0.56%)
  • Volume:
    390,707
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    18.600 - 18.940

EVTG Overview

Prev. Close
18.915
Day's Range
18.6-18.94
Revenue
510.75M
Open
18.92
52 wk Range
14.8-37.39
EPS
-1.02
Volume
390,707
Market Cap
3.32B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
484,864
P/E Ratio
-18.43
Beta
0.963
1-Year Change
-46.52%
Shares Outstanding
176,702,738
Next Earnings Date
Mar 30, 2023
What is your sentiment on Evotec AG?
or
Market is currently closed. Voting is open during market hours.

Evotec AG O.N. Analysis

Evotec AG O.N. Company Profile

Evotec AG O.N. Company Profile

Employees
4521
Market
Germany
  • Type:Equity
  • Market:Germany
  • ISIN:DE0005664809
  • WKN:566480

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Read More

Analyst Price Target

Average27.100 (+44.072% Upside)
High50.000
Low20.000
Price18.810
No. of Analysts13
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsSellBuyBuyStrong BuyStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Sell
  • To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
    0
    • lol railing Melvin Capital left and right
      0
      • Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
        0
    • The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
      0